{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:32:22Z","timestamp":1761514342337},"reference-count":17,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2019]]},"DOI":"10.3960\/jslrt.18037","type":"journal-article","created":{"date-parts":[[2019,2,6]],"date-time":"2019-02-06T22:37:34Z","timestamp":1549492654000},"page":"29-33","source":"Crossref","is-referenced-by-count":3,"title":["Myelodysplastic\/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS\/MPN with RS-T) complicated by hyperleukocytosis and gene analysis in relation to leukocytosis"],"prefix":"10.3960","volume":"59","author":[{"given":"Yumi","family":"Aoyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuko","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taiichi","family":"Kodaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Tsunemine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuto","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoo","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daichi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","unstructured":"1 Orazi A, Hasserjian RP, Cazzola M, Thiele M, Malcovati L. Myelodysplastic\/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4<sup>th<\/sup> ed, Lyon, International Agency for Research on Cancer. 2017; pp. 93-94."},{"key":"2","unstructured":"2 Vardiman JW, Bennett JM, Bain BJ, <i>et al.<\/i> Myelodysplastic\/myeloproliferative neoplasm unclassifiable. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4<sup>th<\/sup> ed, Lyon, International Agency for Research on Cancer. 2008; pp. 85-86."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Kralovics R, Passamonti F, Buser AS <i>et al.<\/i> A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005; 352: 1779-1790.","DOI":"10.1056\/NEJMoa051113"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Yoshida K, Sanada M, Shiraishi Y <i>et al.<\/i> Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011; 478: 64-69.","DOI":"10.1038\/nature10496"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Broseus J, Florensa L, Zipperer E <i>et al.<\/i> Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis. Haematologica. 2012; 97: 1036-1041.","DOI":"10.3324\/haematol.2011.053918"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Inoue D, Abdel-Wahab O. Modeling SF3B1 mutations in cancer: Advances, challenges, and opportunities. Cancer Cell. 2016; 30: 371-373.","DOI":"10.1016\/j.ccell.2016.08.013"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Arber DA, Orazi A, Hasserjian R <i>et al.<\/i> The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127: 2391-2405.","DOI":"10.1182\/blood-2016-03-643544"},{"key":"8","unstructured":"8 Thiele J, Kvasnicka HM, Orazi A, <i>et al.<\/i> Essential thrombocythemia. Revised 4<sup>th<\/sup> ed, Lyon, International Agency for Research on Cancer. 2017; pp. 50-53."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Rumi E, Pietra D, Ferretti V <i>et al.<\/i>. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2014; 123: 1544-1551.","DOI":"10.1182\/blood-2013-11-539098"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Passamonti F. How I treat polycythemia vera. Blood. 2012; 120: 275-284.","DOI":"10.1182\/blood-2012-02-366054"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Vannucchi AM, Antonioli E, Guglielmelli P <i>et al.<\/i> Clinical profile of homozygous JAK2 617V&gt;F mutation in patients with polycythemia vera or essential thrombocythemia. Blood. 2007; 110: 840-846.","DOI":"10.1182\/blood-2006-12-064287"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Kittur J, Knudson RA, Lasho TL <i>et al.<\/i> Clinical correlates ofJAK2V617F allele burden in essential thrombocythemia. Cancer. 2007; 109: 2279-2284.","DOI":"10.1002\/cncr.22663"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Kurtin PJ, Dewald GW, Shields DJ, Hanson CA. Hematologic disorders associated with deletions of chromosome 20q: a clinicopathologic study of 107 patients. Am J Clin Pathol. 1996; 106: 680-688.","DOI":"10.1093\/ajcp\/106.5.680"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Braun T, de Botton S, Taksin AL <i>et al.<\/i> Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: A report on 62 cases. Leuk Res. 2011; 35: 863-867.","DOI":"10.1016\/j.leukres.2011.02.008"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Delic S, Rose D, Kern W <i>et al.<\/i> Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera. Br J Haematol. 2016; 175: 419-426.","DOI":"10.1111\/bjh.14269"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Barbui T, Carobbio A, Rambaldi A, Finazzi G. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? Blood. 2009; 114: 759-763.","DOI":"10.1182\/blood-2009-02-206797"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Cazzola M, Rossi M, Malcovati L. Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms. Blood. 2013; 121: 260-269.","DOI":"10.1182\/blood-2012-09-399725"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/59\/1\/59_18037\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T04:22:52Z","timestamp":1558758172000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/59\/1\/59_18037\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.18037","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]}}}